Natural history of alpha mannosidosis a longitudinal study

Michael Beck, Klaus J Olsen, James E Wraith, Jiri Zeman, Jean-Claude Michalski, Paul Saftig, Jens Fogh, Dag Malm, Michael Beck, Klaus J Olsen, James E Wraith, Jiri Zeman, Jean-Claude Michalski, Paul Saftig, Jens Fogh, Dag Malm

Abstract

Background: Alpha-Mannosidosis is a rare lysosomal storage disorder, caused by the deficiency of the enzyme alpha-Mannosidase. Clinically it is characterized by hearing impairment, skeletal and neurological abnormalities and mental retardation. In order to characterize the clinical features and disease progression of patients affected by alpha-Mannosidosis, a survey study was conducted. 43 patients from 4 European countries participated in this longitudinal study. Age range of the participants was 3 to 42 years. For each patient a medical history, complete physical and neurological examination, joint range of motion and assessment of physical endurance and of lung function were completed. In addition, serum and urinary oligosaccharide levels were analysed.

Methods: In this multicenter longitudinal study clinical data of 43 alpha-Mannosidosis patients were collected. In addition to objective clinical measurements biochemical assays were performed.

Results: Data analysis revealed a wide spectrum of clinical presentation regarding the severity and disease progression. Most clinical abnormalities were observed in the musculoskeletal and neurological system. All patients showed mental retardation and hearing loss from early childhood. An impairment in physical endurance was revealed by the 6-minute walk and 3-minute stair stair climb tests. There was only slight progression of a few clinical findings: Psychiatric troubles in both groups essentially, and respiratory dysfunction under 18 years. The serum and urinary oligosaccharide levels were increased in all affected individuals and correlated well with the 6-minute walk and 3-minute stair climb test results.

Conclusions: This study confirms that alpha-Mannosidosis is a very heterogeneous disorder regarding both, disease severity and progression. As it has been shown that Mannosidosis patients are able to perform lung function tests and the 6MWT and stair-climb test, these clinical parameters apparently can be used as clinical endpoints for clinical trials. Oligosaccharide levels appeared correlated with functional testing and may serve as biomarkers of disease severity, progression and response to treatment.

Trial registration: ClinicalTrials.gov Identifier = NCT00498420 and EuropeanCommission FP VI contract LHSM-CT-2006-018692.

Figures

Figure 1
Figure 1
Height of males with Alpha-Mannosidosis. Outer lines indicate - 2 SD and + 2 SD.
Figure 2
Figure 2
Height of females with alpha-mannosidosis. Outer lines indicate - 2 SD and + 2 SD.
Figure 3
Figure 3
Change of height of children and adults over time.
Figure 4
Figure 4
Hearing testing - bone conduction (dB HL). Mean ± SE (= 1 Standard deviation).
Figure 5
Figure 5
Hearing testing - air conduction: conventional frequency range (dB HL) mean ± SE (= 1 Standard deviation).
Figure 6
Figure 6
Hearing testing air conduction: high frequency range (dB HL) Mean ± SE (= 1 Standard deviation).
Figure 7
Figure 7
6-minute walk test: percentage of normal ± SE.
Figure 8
Figure 8
Lung function: range of FVC, expressed as percentage of expected depending on age, size and sex.
Figure 9
Figure 9
Lung function: percentage of predicted forced expiratory volume during first second.
Figure 10
Figure 10
6 minutes walk test (% of predicted) versus oligosaccharide level in urine by age group. Correlation Factor = 0,61602, P-Value = 0,0014).
Figure 11
Figure 11
Minutes stair climb test versus oligosaccharide level in urine by age group. Correlation Factor = 0,56805, P-Value = 0,0072).

References

    1. Desnick RJ, Sharp HL, Grabowski GA, Brunning RD, Quie PG, Sung JH, Gorlin RJ, Ikonne JU. Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediatr Res. 1976;10:985–996. doi: 10.1203/00006450-197612000-00008.
    1. Bach G, Kohn G, Lasch EE, El Massri M, Ornoy A, Sekeles E, Legum C, Cohen MM. A new variant of mannosidosis with increased residual enzymatic activity and mild clinical manifestation. Pediatr Res. 1978;12:1010–1015. doi: 10.1203/00006450-197810000-00012.
    1. Malm D, Nilssen O. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21. doi: 10.1186/1750-1172-3-21.
    1. Riise Stensland HM, Klenow HB, Nguyen LV, Hansen GM, Malm D, Nilssen O. Identification of 83 novel alpha-mannosidosis-associated sequence variants: functional analysis of MAN2B1 missense mutations. Hum Mutat. 2012;33:511–520. doi: 10.1002/humu.22005.
    1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. doi: 10.1001/jama.281.3.249.
    1. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–156.
    1. The HUE-MAN Project. Towards the development of an effective enzyme replacement therapy for human alpha-mannosidosis. [ ]
    1. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
    1. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, Geiger H, Loeckinger A, Stein JI. Six-minute walk test in children and adolescents. J Pediatr. 2007;150:395–399. doi: 10.1016/j.jpeds.2006.12.052. 399 e391-392.
    1. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil. 2001;21:87–93. doi: 10.1097/00008483-200103000-00005.
    1. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158:1384–1387. doi: 10.1164/ajrccm.158.5.9710086.
    1. Balfour-Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R. A step in the right direction: assessing exercise tolerance in cystic fibrosis. Pediatr Pulmonol. 1998;25:278–284. doi: 10.1002/(SICI)1099-0496(199804)25:4<278::AID-PPUL8>;2-G.
    1. Bolton JW, Weiman DS, Haynes JL, Hornung CA, Olsen GN, Almond CH. Stair climbing as an indicator of pulmonary function. Chest. 1987;92:783–788. doi: 10.1378/chest.92.5.783.
    1. Statement ATS. Standardization of spirometry, 1994, Update 1995. Am J Respir Crit Care Med. 1995;152:1107–1136.
    1. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis care and research: the official journal of the Arthritis Health Professions Association. 1992;5:119–129.
    1. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–1769. doi: 10.1002/art.1780371209.
    1. Morelle W, Page A, Michalski JC. Electrospray ionization ion trap mass spectrometry for structural characterization of oligosaccharides derivatized with 2-aminobenzamide. Rapid communications in mass spectrometry : RCM. 2005;19:1145–1158. doi: 10.1002/rcm.1900.
    1. Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega AC, Schaefer F, Jager KJ. Use of national and international growth charts for studying height in European children: development of up-to-date European height-for-age charts. PLoS One. 2012;7:e42506. doi: 10.1371/journal.pone.0042506.
    1. Yunis JJ, Lewandowski RC Jr, Sanfilippo SJ, Tsai MY, Foni I, Bruhl HH. Clinical manifestations of mannosidosis - a longitudinal study. Am J Med. 1976;61:841–848. doi: 10.1016/0002-9343(76)90408-3.
    1. Ara JR, Mayayo E, Marzo ME, Guelbenzu S, Chabás A, Pina MA, Calderón C. Neurological impairment in α-mannosidosis: a longitudinal clinical and MRI study of a brother and sister. Childs Nerv Syst. 1999;15:369–371. doi: 10.1007/s003810050416.
    1. Noll RB, Netzloff ML, Kulkarni R. Long-term follow-up of biochemical and cognitive functioning in patients with mannosidosis. Arch Neurol. 1989;46:507–509. doi: 10.1001/archneur.1989.00520410041020.
    1. Chester MA, Lundblad A, Ockerman PA, Autio S. In: Genetic Errors of Glycoprotein Metabolism. Durand P, O’Brien JF, editor. Milan: Edi-Ermes; 1982. Mannosidosis; pp. 89–122.
    1. Autio S, Louhimo T, Helenius M. The clinical course of mannosidosis. Ann Clin Res. 1982;14:93–97.
    1. Ahmmed AU, O’Halloran SM, Roland NJ, Starkey M, Wraith JE. Hearing loss due to mannosidosis and otitis media with effusion. A case report and review of audiological assessments in children with otitis media with effusion. J Laryngol Otol. 2003;117:307–309.
    1. Arbisser AI, Murphree AL, Garcia CA, Howell RR. Ocular findings in mannosidosis. Am J Ophthalmol. 1976;82:465–471.
    1. Springer C, Gutschalk A, Meinck HM, Rohrschneider K. Late-onset retinal dystrophy in alpha-mannosidosis. Graefes Arch Clin Exp Ophthalmol. 2005;243:1277–1279. doi: 10.1007/s00417-004-1084-7.
    1. Matsuura F, Nunez HA, Grabowski GA, Sweeley CC. Structural studies of urinary oligosaccharides from patients with mannosidosis. Arch Biochem Biophys. 1981;207:337–352. doi: 10.1016/0003-9861(81)90041-2.
    1. Hubbard SC, Robbins PW. Synthesis and processing of protein-linked oligosaccharides in vivo. J Biol Chem. 1979;254:4568–4576.
    1. Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE, Roberts J, Ketteridge D, Hopwood JJ. et al.Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) Am J Med Genet A. 2005;134A:144–150. doi: 10.1002/ajmg.a.30579.
    1. Blanz J, Stroobants S, Lullmann-Rauch R, Morelle W, Ludemann M, D’Hooge R, Reuterwall H, Michalski JC, Fogh J, Andersson C, Saftig P. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum Mol Genet. 2008;17:3437–3445. doi: 10.1093/hmg/ddn237.
    1. Damme M, Stroobants S, Walkley SU, Lullmann-Rauch R, D’Hooge R, Fogh J, Saftig P, Lubke T, Blanz J. Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. J Neuropathol Exp Neurol. 2011;70:83–94. doi: 10.1097/NEN.0b013e31820428fa.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera